Gut

Beyond Spigelman: time-adaptive duodenal cancer risk in familial adenomatous polyposis – results from a retrospective two-centre study (DRACO)

Background Duodenal cancer is a leading cause of cancer-related mortality in familial adenomatous polyposis (FAP), yet the ...
Gut

KIF13B emerges as a key player in alcohol-associated liver steatosis

Alcohol-associated liver disease (ALD) is a major global health problem and a leading cause of liver-related morbidity and ...
Gut

Beyond the usual suspects: haemorrhagic shock secondary to massive obscure gastrointestinal bleeding

A 49-year-old woman with alcohol-related cirrhosis (Child-Pugh B8, MELD 11) and 11 months of abstinence presented with per ...
Gut

B4CeD: harmonising scientific terms and concepts in early coeliac disease

The lack of consensus on concepts relevant to the early development of coeliac disease (CeD) may hinder research and ...
Gut

From Bristol to Rome, from recurrent abdominal pain to disorders of gut-brain interaction

The first formal paediatric prevalence study of abdominal pain was conducted in 1958 in Bristol, UK. In their seminal paper ...
gut.bmj

Burden of liver fibrosis and steatosis coexisting with hepatitis B or C infection in China: a population-based study from the 2020 National Serological Survey

3 National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, ...
gut.bmj

Impact of non-enteric-coated pancreatic enzyme replacement therapy (NEPERT) on pain in patients with chronic pancreatitis: a double-blind, parallel-group, placebo-controlled ...

Background Pain in chronic pancreatitis (CP) is multifactorial. Efficacy of pancreatic enzyme replacement therapy (PERT) for pain remains uncertain. Objective To assess the effect of ...
gut.bmj

International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update

The recent conditional US Food and Drug Administration (FDA) approval of two therapies, resmetirom (Rezdiffra) and semaglutide (Wegovy), marks the first time clinicians have pharmacological therapy ...
gut.bmj

Ferroptosis, immune activation and MASH-related HCC

Correspondence to Dr Bruno Ramos-Molina; brunoramosmolina{at}gmail.com; Dr Mohammad Shafi Kuchay; drshafikuchay{at}gmail.com Metabolic dysfunction-associated steatohepatitis (MASH) involves a complex ...
gut.bmj

Multi-kingdom signatures of the gut microbiome in Lynch syndrome: a prospective model for colorectal cancer evolution

Recent work in Gut has highlighted multi-kingdom interactions between gut bacteria and bacteriophage (‘phage’) as contributors to Crohn’s disease.1 Whether similar alterations characterise colorectal ...
gut.bmj

Deferring first surveillance to 3 years after colorectal ESD is not supported by these data

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
gut.bmj

Enhanced acetate uptake and metabolism in endothelial cells promote tumour angiogenesis and immunosuppression by increasing histone acetylation

Background Acetate is the metabolic precursor of acetyl-coenzyme A (CoA), fuelling histone acetylation. Objective We aimed to investigate whether the acetate-acetylation axis is hijacked in tumour ...